Table 1.

Information of clinical trials and imaging data that was included for retrospective analysis in this study. Clinical benefit is presented for all patients who received baseline images. The proportion of patients with heterogenous change (having both decreasing or disappeared and increasing or new lesion-ROI) was calculated for all patients who received baseline and follow-up images

Dataset	CALGB50303 - DLBCL	ACRIN 6668 - NSCLC
Clinical Trial Number	NCT00118209	NCT00083083
Imaging Timepoints	Baseline 2–3 weeks after cycle 2 of chemotherapy	Baseline 14–16 weeks post radiotherapy
Disease	Diffuse large B-cell lymphoma	Non-small cell lung cancer
Treatments	Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)	Chemoradiotherapy
Patients who received baseline and follow-up FDG PET/CT images (N)	127	114
Number of lesion-ROI on baseline Median [range]	9 [0-110]	3 [0–15]
Overall survival (Days) Median [range]	1845 [82–3293]	753 [118–2326]
Percentage of patients with heterogeneous change (%)	51/127 (40.1%)	101/114 (88.6%)